TERT and its binding protein: overexpression of GABPA/B in high grade gliomas.
GABPA
GABPB
TERT
astrocytoma
glioma
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
13
11
2020
accepted:
22
03
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
2
7
2021
Statut:
epublish
Résumé
Enhanced expression of TERT in gliomas is a result of two hotspot mutations, C228T and C250T, at the promoter region. GA-binding proteins selectively bind at these positions, respectively, causing an activation of the promoter and overexpression of TERT. GABP is a multimeric protein consisting of GABPA and GABPB with its isoforms GABPB1, GABPB1-L, GABPB1-S, GABPB2. In this study, we investigated the mRNA expression and association between TERT and GABPA/B isoforms in tumor samples of different glioma grades. The expression was determined by quantitative real-time PCR and the results were statistically analyzed. We present that TERT is mainly expressed in primary glioblastomas. All GA-binding proteins progress through the glioma grades and have the highest expression levels in secondary glioblastomas. In secondary glioblastomas after chemotherapy, GABPB1 and GABPB1-L are expressed on a lower level than without treatment. In high grades, TERT and GABPA, GAPB1, GABPB1-L, GABPB1-S are upregulated compared to low grades. Between primary and secondary glioblastomas with and without chemotherapy, TERT is elevated in the former while GABPB1 is increased in the secondary glioblastomas. GABPA and GABPB1, GABPB1-L and GABPB1-S positive correlate in primary glioblastomas. The present study confirms the upregulation of TERT in primary glioblastomas while all GABP proteins rise with the malignancy of the gliomas. Further investigations must be made to elucidate the relation between TERT and all GABP proteins as it may play a key role in the gliomagenesis.
Identifiants
pubmed: 34194624
doi: 10.18632/oncotarget.27985
pii: 27985
pmc: PMC8238242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1271-1280Informations de copyright
Copyright: © 2021 Papazacharias et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.
Références
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Neuro Oncol. 2016 Aug;18(8):1099-108
pubmed: 26957363
Genes (Basel). 2016 Aug 18;7(8):
pubmed: 27548225
Acta Neuropathol. 2013 Aug;126(2):267-76
pubmed: 23764841
Int J Oncol. 2006 Jun;28(6):1555-60
pubmed: 16685456
Cancer Cell. 2018 Sep 10;34(3):513-528.e8
pubmed: 30205050
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1531-1547
pubmed: 29200109
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818802318
pubmed: 30259794
Cell Rep. 2013 May 30;3(5):1663-77
pubmed: 23684612
J Neurooncol. 2019 Mar;142(1):111-118
pubmed: 30535594
Neuro Oncol. 2015 Sep;17(9):1231-40
pubmed: 25681309
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Cancer Res. 2004 Oct 1;64(19):6892-9
pubmed: 15466178
Oncol Lett. 2019 Jan;17(1):95-102
pubmed: 30655743
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Handb Clin Neurol. 2016;134:361-80
pubmed: 26948366
Acta Neuropathol. 2012 Nov;124(5):615-25
pubmed: 22886134
Science. 2007 Mar 30;315(5820):1850-3
pubmed: 17395830
Oncotarget. 2014 May 30;5(10):3399-407
pubmed: 24930669
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17426-31
pubmed: 24101484
J Biol Chem. 1995 Oct 6;270(40):23627-33
pubmed: 7559529
Cancer Sci. 2008 Aug;99(8):1528-38
pubmed: 18754863
Br J Cancer. 2014 Nov 11;111(10):2024-32
pubmed: 25314060
Acta Neuropathol. 2013 Dec;126(6):931-7
pubmed: 23955565
Oncotarget. 2015 Jun 30;6(18):16663-73
pubmed: 26143636
Science. 1991 Aug 16;253(5021):789-92
pubmed: 1876836
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Blood Cells Mol Dis. 2004 Jan-Feb;32(1):143-54
pubmed: 14757430
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Science. 2015 May 29;348(6238):1036-9
pubmed: 25977370
EMBO J. 1994 Mar 15;13(6):1396-402
pubmed: 8137823
Genes Dev. 1994 Aug 1;8(15):1853-65
pubmed: 7958862